Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Electronic Capsule Technology the Basis for Innovations in Personalized Medicine for Women

By LabMedica International staff writers
Posted on 30 Jan 2013
Two European biomedical companies have agreed to collaborate on the development of personalized diagnostic and therapeutic products in the area of women’s health.

Medimetrics BV (Heilbronn, Germany) and the newly formed LiGalli (The Hague, the Netherlands) will be pooling their expertise to develop and produce medical drug delivery and monitoring devices based on Medimetrics' IntelliCap electronic capsule. More...


The IntelliCap electronic capsule is a unique ingestible device that combines five technologies: electronically controlled drug release, laboratory measurement capability, GI tract navigation in the body, two-way real time communication, and the novel operating system. The capsule contains a fluid reservoir and a micro-fluidic pump capable of pumping fluids, pastes, or suspensions. Operation of the pump is controlled by an integrated microprocessor. The IntelliCap also contains sensors that measure the pH and temperature of the pill’s local environment and an ultralow power radio transceiver that allows two-way communication to a data-monitoring/control unit. It is powered by an on-board battery and its electronics are fully sealed to ensure biocompatibility.

LiGalli will contribute its in-depth experience in pharmaceutical and gynecological products to the partnership.

Dr.Willem de Laat, founder of LiGalli said, “This is a significant, but also a logical, step forward in the move towards personalized medicine, improving the diagnostic and therapeutic tools available to patients. Having access to this groundbreaking technology opens the door to developing individualized therapies, which for the first time could meet a woman’s specific needs. It then becomes possible to perform continuous diagnosis monitoring or time exactly when a therapy was delivered, adapt the quantity, and even interrupt the schedule, if necessary.”

Dr. Olaf Weiner, CEO of Medimetrics, said, “The new collaboration adds an exciting dimension within the area of women’s health, creating new and improved therapeutic opportunities for patients. More and more companies are recognizing the potential of our IntelliCap technology, seeking to capitalize on its diagnostic and drug delivery functionalities. It is already widely used by the pharmaceutical industry to rationalize and speed up the development of modified release formulations and dosage forms. By tailoring drug delivery in this way, it is also possible for patients to take their medication less frequently without compromising on efficacy.”

Related Links:
Medimetrics B.V.



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.